Advertisement

Photodynamic Therapy in Dermatology

  • Rolf-Markus Szeimies
  • Sigrid Karrer
  • Christoph Abels
  • Michael Landthaler
  • Craig A. Elmets

Abstract

Photodynamic therapy refers to a new form of phototherapy in which nonpsoralen photosensitizing drugs are administered systemically or topically to an individual. The drugs alone are inactive, but once activated by high-intensity light usually from a laser, they are exceptionally effective at inhibiting the growth of hyperproliferative tissues. PDT was originally designed for the treatment of malignancies because of the unique property of several photosensitizers to localize preferentially within tumors. Porfimer sodium (Photofrin), a first generation PDT photosensitizer, has already received regulatory approval in the USA, Canada, Japan, and Europe for the management of bladder, esophageal, and lung cancers. Although PDT has not been formally approved for dermatological malignancies, its efficacy in the treatment of superficial skin cancer has been demonstrated in several clinical studies [23, 38, 43, 85,103,125, 151, 163, 185]. Clinical trials are currently being conducted for this indication and approval is likely within the next few years. Because of the accessibility of the skin, there is increasing interest in using this novel form of therapy for psoriasis and other benign cutaneous disorders as well.

Keywords

Photodynamic Therapy Basal Cell Carcinoma Actinic Keratose Mycosis Fungoides Nevoid Basal Cell Carcinoma Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abels C, Dellian M, Szeimies RM, Steinbach P, Richert C, Goetz AE (1996) Targeting of the tumor microcirculation with a new photosensitizer. In: Ehrenberg B, Jori G, Moan J (eds) Photochemotherapy: photodynamic therapy and other modalities. Proc SPIE 2625x64–169Google Scholar
  2. 2.
    Abels C, Heil P, Dellian M, Kuhnle GEH, Baumgartner R, Goetz AE (1994) In vivo kinetics and spectra of 5–aminolevulinic acid-induced fluorescence in an amelanotic melanoma of the hamster. Br J Cancer 70: 826–833PubMedCrossRefGoogle Scholar
  3. 3.
    Agarwal R, Korman NJ, Mohan RR, Feyes DK, Jawed S, Zaim MT, Mukhtar H (1996) Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin. Photochem Photobiol 63547–552Google Scholar
  4. 4.
    Ahmad N, Feyes DK, Agarwal R, Mukhtar H (1998) Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci USA 956977–6982Google Scholar
  5. 5.
    Allison RR, Mang TS (1997) A phase II/III clinical study for the treatment of HIV-associated cutaneous Kaposi’s sarcoma with tin ethyl etiopurpurin (SnET2)-induced photodynamic therapy. Presented at the European Cancer Conference (ECCo9), Hamburg, GermanyGoogle Scholar
  6. 6.
    Allison RR, Mang TS, Wilson BD (1998) Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cut Med Surg 17: 153–163CrossRefGoogle Scholar
  7. 7.
    Ammann R, Hunziker T (1995) Photodynamic therapy for mycosis fungoides after topical photosensitization with 5–aminolevulinic acid. J Am Acad Dermatol 33: 541PubMedCrossRefGoogle Scholar
  8. 8.
    Anderson CY, Elmets CA (manuscript in preparation)Google Scholar
  9. 9.
    Anderson C, Hrabovsky S, McKinley Y, Tubesing K, Tang HP, Mukhtar H and Elmets CA (1997) Phthalocyanine (Pc) photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Photochem Photobiol 65895–9O1Google Scholar
  10. 10.
    Aramendia PF, Redmond RW, Nonell S, Schuster W, Braslaysky SE, Schaffner K, Vogel E (1986) The photophysical properties of porphycenes: potential photodynamic therapy agents. Photochem Photobiol 44555–559Google Scholar
  11. 11.
    Athar M, Mukhtar H, Elmets CA, Zaim MT, Lloyd JR, Bickers DR (1988) In situ evidence for the involvement of superoxide anions in cutaneous porphyrin photosensitization. Biochem Biophys Res Commun 151: 1054–1059PubMedCrossRefGoogle Scholar
  12. 12.
    Athar M, Elmets CA, Bickers DR, Mukhtar H (1989) A novel mechanism for the generation of superoxide anions in porphyrin mediated cutaneous photosensitization: Activation of the xanthine oxidase pathway. J Clin Invest 83x137–1143Google Scholar
  13. 13.
    Babich D, Whitaker J, Conti C, Blaird-Wagner D, Stoll HL, Dozier S, Oseroff AR (1996) Treatment of all stages of cutaneous T-cell lymphomas with fractionated photodynamic therapy using topical ó-aminolevulinic acid. J Invest Dermatol 106: 840Google Scholar
  14. 14.
    Bandieramonte G, Marchesini R, Melloni E, Andreoli C, Di pietro D, Spinelli P, Pava G, Zunino F, Emanuelli H (1984) Laser phototherapy following HpD administration in superficial neoplastic lesions. Tumori 70: 327–334PubMedGoogle Scholar
  15. 15.
    Batlle AM del C (1993) Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B: Biol 20: 5–22CrossRefGoogle Scholar
  16. 16.
    Bellnier DA, Ho YK, Pandey RK, Missert JR, Dougherty TJ (1989) Distribution and elimination of Photofrin II in mice. Photochem Photobiol 50: 221–228PubMedCrossRefGoogle Scholar
  17. 17.
    Ben-Hur E, Horowitz B (1995) Advances in photochemical approaches for blood sterilization. Photochem Photobiol 62: 383–388PubMedCrossRefGoogle Scholar
  18. 18.
    Berg H, Bauer E, Gollmick FA, Diezel W, Böhm F, Meffert H, Sönnichsen N (1985) Photodynamic hematoporphyrin therapy of psoriasis. In: Jori G, Perria C (eds) Photodynamic therapy of tumors and other diseases. Progetto Editore, Padova, pp 337–343Google Scholar
  19. 19.
    Berlin NI, Neuberger A, Scott JJ (1956) The metabolism of S-aminolevulinic acid. 1. Normal pathways, studied with the aid of 15N. Biochem J 64: 8o - 90Google Scholar
  20. 20.
    Bockstahler LE, Coohill TP, Hellman KB, Lytle CD, Roberts JE (1979) Photodynamic therapy for herpes simplex: a critical review. Pharmacol Ther 4: 473–499PubMedCrossRefGoogle Scholar
  21. 21.
    Boehncke WH, König K, Kaufmann R, Scheffold W, Prümmer 0, Sterry W (1994) Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res 286:30o -303Google Scholar
  22. 22.
    Boehncke WH, König K, Ruck A, Kaufmann R, Sterry W (1994) In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. Acta Derm Venereol (Stockh) 74: 201–205Google Scholar
  23. 23.
    Boehncke WH, Sterry W, Kaufmann R (1994) Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 343: 801PubMedCrossRefGoogle Scholar
  24. 24.
    Buchanan RB, Carruth JAS, McKenzie AL, Williams SR (1989) Photodynamic therapy in the treatment of malignant tumours of the skin and head and neck. Eur J Surg Oncol 15: 400–406PubMedGoogle Scholar
  25. 25.
    Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB (1994) Superficial photodynamic therapy with topical 5–aminolevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 69: 605–608PubMedCrossRefGoogle Scholar
  26. 26.
    Calzavara F, Tornio L (1991) Photodynamic therapy: clinical experience at the department of radiotherapy at Padova general hospital. J Photochem Photobiol B Biol 11: 91–95CrossRefGoogle Scholar
  27. 27.
    Calzavara-Pinton PG (1995) Repetitive photodynamic therapy with topical Saminolevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B Biol 29: 53–57CrossRefGoogle Scholar
  28. 28.
    Castellani A, Page GP, Concioli M (1963) Photodynamic effect of hematoporphyrin on blood microcirculation. J Pathol Bacteriol 86: 99–102PubMedCrossRefGoogle Scholar
  29. 29.
    de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W (1996) Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 56: 2908–2911PubMedGoogle Scholar
  30. 30.
    de Vree WJ, Essers MC, Koster JF, Sluiter W (1997) Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res 57: 2555–2558PubMedGoogle Scholar
  31. 31.
    Dellian M, Abels C, Kuhnle GE, Goetz AE (1995) Effects of photodynamic therapy on leukocyte-endothelium interaction: differences between normal and tumour tissue. Br J Cancer 72: 1125–1130PubMedCrossRefGoogle Scholar
  32. 32.
    Dellian M, Walenta S, Gamarra F, Kuhnle GE, Mueller-Klieser W, Goetz AE (1994) High-energy shock waves enhance hyperthermic response of tumors: effects on blood flow, energy metabolism, and tumor growth. J Natl Cancer Inst 86: 287–293PubMedCrossRefGoogle Scholar
  33. 33.
    Dilkes MG, De Jode ML, Rowntree-Taylor A (1997) m-THPC photodynamic therapy for head and neck cancer. Lasers Med Sci 11: 23–30Google Scholar
  34. n Photodynamic Therapy in Dermatology 239Google Scholar
  35. 34.
    Dougherty TJ (1981) Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol 77x22–124Google Scholar
  36. 35.
    Dougherty TJ (1996) A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med Surg 14: 219–221PubMedGoogle Scholar
  37. 36.
    Dougherty TJ, Gomer CJ, Henderson BW, Joni G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90: 889–905PubMedCrossRefGoogle Scholar
  38. 37.
    Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG (1975) Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 55: 115–121Google Scholar
  39. 38.
    Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A (1978) Photoradiation therapy for the treatment of malignant tumors. Cancer Res 38: 2628–2635PubMedGoogle Scholar
  40. 39.
    Elmets CA, Bowen KD (1986) Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res 46x608–1611Google Scholar
  41. 40.
    Emtestam L, Berglund L, Angelin B, Drummond GS, Kappas A (1989) Tinprotoporphyrin and long wavelength ultraviolet light in treatment of psoriasis. Lancet 1: 1231–1233PubMedCrossRefGoogle Scholar
  42. 41.
    Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI (1990) Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst 82: 34–39PubMedCrossRefGoogle Scholar
  43. 42.
    Feyh J, Gutmann R, Leunig A (1993) Die photodynamische Lasertherapie im Bereich der Hals-, Nasen-, Ohrenheilkunde. Laryngo Rhino Otol 72: 273–278Google Scholar
  44. 43.
    Fijan S, Hönigsmann H, Ortel B (1995) Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 133: 282–288PubMedCrossRefGoogle Scholar
  45. 44.
    Fijan S, Hönigsmann H, Tanew A (1996) Photodynamic therapy of keratoacanthoma using topical delta-aminolevulinic acid. J Invest Dermatol 106: 945 (abstract)Google Scholar
  46. 45.
    Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14: 323–328PubMedGoogle Scholar
  47. 46.
    Fingar VH, Wieman TJ, Doak KW (1990) Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 50: 2599–2603PubMedGoogle Scholar
  48. 47.
    Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB (1992) The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 524914–4921Google Scholar
  49. 48.
    Fingar VH, Wieman TJ, Karavolos PS, Doak KW, Ouellet R, van Lier JE (1993) The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochem Photobiol 58: 251–258PubMedCrossRefGoogle Scholar
  50. 49.
    Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P (1998) Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical 8–aminolevulinic acid photodynamic therapy. Arch Dermatol 134: 821–826PubMedCrossRefGoogle Scholar
  51. 50.
    Forbes IJ, Cowled PA, Leong ASY, Ward AD, Black RB, Blake AJ, Jacka FJ (1980) Phototherapy of human tumours using hematoporphyrin derivative. Med J Aust 2489–493Google Scholar
  52. 51.
    Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA (1991) Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res 51: 3261–3266PubMedGoogle Scholar
  53. 52.
    Frank RGJ, Bos JD, Vandermeulen FW, Sterenborg HJCM (1996) Photodynamic therapy for condylomata acuminata with local application of 5–aminolevulinic acid. Genitourin Med 72: 70–71PubMedGoogle Scholar
  54. 53.
    Friedrich EG (1973) Relief for herpes vulvitis. Obstet Gynecol 41: 74–77PubMedGoogle Scholar
  55. 54.
    Fritsch C, Verwohlt B, Bolsen K, Ruzicka T, Goerz G (1996) Influence of topical photodynamic therapy with 5–aminolevulinic acid on porphyrin metabolism. Arch Dermatol Res 288: 517–521PubMedCrossRefGoogle Scholar
  56. 55.
    Gniazdowska B, Rueff F, Hillemann P, Przybilla B (1998) Allergic contact dermatitis from 8–aminolevulinic acid used for photodynamic therapy. Contact Derm 38348–349Google Scholar
  57. 56.
    Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW (1997) Altered expression of interleukin 6 and interleukin to as a result of photodynamic therapy in vivo. Cancer Res 57: 3904–3909PubMedGoogle Scholar
  58. 57.
    Gomer CJ, Ferrario A, Rucker N, Wong S, Lee AS (1991) Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photo-sensitization. Cancer Res 51: 6574–6579PubMedGoogle Scholar
  59. 58.
    Gross DJ, Waner M, Schosser RH, Dinehart SM (1990) Squamous cell carcinoma of the lower lip involving a large cutaneous surface. Photodynamic therapy as an alternative therapy. Arch Dermatol 126: 1148–1150Google Scholar
  60. 59.
    Guardiano M, Biolo R, Jori G, Schaffner K (1989) Tetra-n-propylporphycene as a tumour localizer: pharmacokinetic and phototherapeutic studies in mice. Cancer Lett 44: 1–6PubMedCrossRefGoogle Scholar
  61. 60.
    Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, Jain RK (1992) Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52: 1993–1995PubMedGoogle Scholar
  62. 61.
    Hanania J, Malik Z (1992) The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett 65: 127–131PubMedCrossRefGoogle Scholar
  63. 62.
    Harth Y, Hirshowitz B, Kaplan B (1998) Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol Surg 24: 723–726PubMedCrossRefGoogle Scholar
  64. 63.
    Hebeda KM, Huizing MT, Brouwer PA, van der Meulen FW, Hulsebosch HJ, Reiss P, Oosting JH, Veenhof CHN, Bakker PJM (1995) Photodynamic therapy in AIDS-related cutaneous Kaposi’s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 10: 61–7oPubMedCrossRefGoogle Scholar
  65. 64.
    Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ (1985) Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 45: 572–576PubMedGoogle Scholar
  66. 65.
    Henderson BW, Donovan JM (1989) Release of prostaglandin E2 from cells by photo-dynamic treatment in vitro. Cancer Res 49: 6896–6900PubMedGoogle Scholar
  67. 66.
    Hendrich C, Hüttmann G, Diddens H, Seara J, Siebert WE (1996) Experimentelle Grundlagen einer photodynamischen Lasertherapie für die chronische Polyarthritis. Orthopäde 25: 30–36PubMedGoogle Scholar
  68. 67.
    Hintschich C, Feyh J, Beyer-Machule C, Riedel K, Ludwig K (1993) Photodynamic laser therapy of basal-cell carcinoma of the lid. Ger J Ophthalmol 2: 212–217PubMedGoogle Scholar
  69. 68.
    Hoerauf H, Hüttmann G, Diddens H, Thiele B, Laqua H (1994) Die Photodynamische Therapie (PDT) des Lidbasalioms nach topischer Applikation von bAminolävulinsäure ( ALA ). Ophthalmologe 91: 824–829Google Scholar
  70. 69.
    Hohenleutner U, Szeimies RM, Landthaler M (1993) Photodynamische Therapie zur Behandlung oberflächlicher Basaliome. In: Braun-Falco O, Plewig G, Meurer M (eds) Fortschritte der praktischen Dermatologie and Venerologie, vol 13. Springer, Berlin Heidelberg New York, pp 472–474Google Scholar
  71. 70.
    Hürlimann AF, Hänggi G, Panizzon RG (1998) Photodynamic therapy of superficial basal cell carcinomas using topical 5–aminolevulinic acid in a nanocolloid lotion. Dermatology 19724$-254Google Scholar
  72. 71.
    Hürlimann AF, Panizzon RA, Burg G (1994) Topical photodynamic treatment of skin tumors and dermatoses. Dermatology 3: 327 (abstract)Google Scholar
  73. 72.
    Jeffes EW, McCullough JL, Weinstein GD, Fergin PD, Nelson JS, Shull TF, Simpson KR, Bukaly LM, Hoffmann WL, Fong NL (1997) Photodynamic therapy of actinic keratosis with topical 5–aminolevulinic acid. A pilot dose-ranging study. Arch Dermatol 133: 727–732Google Scholar
  74. 73.
    Jesionek A, von Tappeiner H (1905) Zur Behandlung der Hautcarcinome mit fluorescierenden Stoffen. Dtsch Arch Klin Med 85: 223–239Google Scholar
  75. 74.
    Jolies CJ, Ott MJ, Straight RC, Lynch DH (1988) Systemic immunosuppression induced by peritoneal photodynamic therapy. Am J Obstet Gynecol 158: 1446–1453Google Scholar
  76. 75.
    Jones CM, Mang T, Cooper M, Wilson DB, Stoll HL (1992) Photodynamic therapy in the treatment of Bowen’s disease. J Am Acad Dermatol 27: 979–982PubMedCrossRefGoogle Scholar
  77. 76.
    Jones LR, Grossweiner LI (1994) Singlet oxygen generation by Photofrin in homogeneous and light-scattering media. J Photochem Photobiol B Biol 26: 249–256CrossRefGoogle Scholar
  78. 77.
    Kappas A, Sassa S, Galbraith RA, Nordmann Y (1989) The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease, 6th edn. McGraw-Hill, New York, pp 1305–1366Google Scholar
  79. 78.
    Karrer S, Abels C, Bäumler W, Ebert A, Landthaler M, Szeimies RM (1996) Topical photodynamic therapy of psoriasis using a novel porphycene dye. J Invest Dermatol 107: 466Google Scholar
  80. 79.
    Karrer S, Abels C, Szeimies RM, Bäumler W, Dellian M, Hohenleutner U, Goetz AE, Landthaler M (1997) Topical application of a first porphycene dye for photodynamic therapy - penetration studies in human perilesional skin and basal cell carcinoma. Arch Dermatol Res 289: 132–137PubMedCrossRefGoogle Scholar
  81. 80.
    Karrer S, Bäumler W, Abels C, Hohenleutner U, Landthaler M, Szeimies RM (1999) Long pulse dye laser for photodynamic therapy - investigations in vitro and in vivo. Lasers Surg Med 25(1)51–59Google Scholar
  82. 81.
    Karrer S, Szeimies RM, Abels C, Wlotzke U, Stolz W, Landthaler M (1999) Epidermodysplasia verruciformis: topical 5–aminolevulinic acid photodynamic therapy. Br J Dermatol 14o: 935–938CrossRefGoogle Scholar
  83. 82.
    Karrer S, Szeimies RM, Ernst S, Abels C, Bäumler W, Landthaler M (1999) Photodynamic inactivation of staphylococci with 5–aminolevulinic acid or photofrin. Lasers Med Sci 1454–61Google Scholar
  84. 83.
    Karrer S, Szeimies RM, Hohenleutner U, Heine A, Landthaler M (1995) Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5–aminolevulinic acid. Dermatology 190: 218–222PubMedCrossRefGoogle Scholar
  85. 84.
    Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B Biol 14: 275–292CrossRefGoogle Scholar
  86. 85.
    Kennedy JC, Pottier RH, Pross DC (1990) Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 6: 143–148CrossRefGoogle Scholar
  87. 86.
    Kerdel FA, Soter NA, Lim HW (1987) In vivo mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. J Invest Dermatol 88: 277–280PubMedCrossRefGoogle Scholar
  88. 87.
    Kessel D (1986) Sites of photosensitization by derivatives of hematoporphyrin. Photochem Photobiol 44489–493Google Scholar
  89. 88.
    Korbelik M, Krosl G (1994) Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 60: 497–502PubMedCrossRefGoogle Scholar
  90. 89.
    Korbelik MJ (1996) Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14329–334Google Scholar
  91. 90.
    Korbelik M, Krosl G, Krosl J, Dougherty GJ (1996) The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 56: 5647–5652PubMedGoogle Scholar
  92. 91.
    Krosl G, Korbelik M, Dougherty GJ (1995) Induction of immune cell infiltration into murine SCCVII tumor by Photofrin-based photodynamic therapy. Br J Cancer 71549–555Google Scholar
  93. 92.
    Krosl G; Korbelik M; Krosl J; Dougherty GJ (1996) Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res 56: 3281–3286PubMedGoogle Scholar
  94. 93.
    Korell M, Untch M, Abels C, Dellian M, Kirschstein M, Baumgartner R, Beyer W, Goetz AE (1995) Einsatz der photodynamischen Lasertherapie in der Gynäkologie. Gynäkol Geburtshilfl Rundsch 35: 90–97CrossRefGoogle Scholar
  95. 94.
    Landthaler M (1992) Premalignant and malignant skin lesions. In: Achauer BM, Vander Kam VM, Berns MW (eds) Lasers in plastic surgery and dermatology. Thieme, New York, pp 34–44Google Scholar
  96. 95.
    Lang S, Baumgartner R, Struck R, Leunig A, Gutmann R, Feyh J (1995) Photodynamische Diagnostik und Therapie von Neoplasien der Gesichtshaut nach topischer Applikation von 5–Aminolävulinsäure. Laryngo Rhino Otol 74: 85–89CrossRefGoogle Scholar
  97. 96.
    Langer S, Abels C, Szeimies RM, Goetz AE (1995) Photodynamic diagnosis and therapy of tumors with topically applied 5–aminolevulinic acid. J Invest Dermatol 105: 511 (abstract)Google Scholar
  98. 97.
    Leunig A, Staub F, Peters J, Leiderer R, Feyh J, Goetz AE (1994) Die Schädigung von Tumorzellen durch die photodynamische Therapie. Laryngo Rhino Otol 73: 102–107CrossRefGoogle Scholar
  99. 98.
    Leunig M, Goetz AE, Gamarra F, Zetterer G, Messmer K, Jain RK (1994) Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster. Br J Cancer 69: 101–103PubMedCrossRefGoogle Scholar
  100. 99.
    Leunig M, Richert C, Gamarra F, Lumper W, Vogel E, Jocham D, Goetz AE (1993) Tumour localisation kinetics of photofrin and three synthetic porphyrinoids in an amelanotic melanoma of the hamster. Br J Cancer 68: 225–234PubMedCrossRefGoogle Scholar
  101. 100.
    Levy JG, Jones CA, Pilson LA (1994) The preclinical and clinical development and potential application of benzoporphyrin derivative. Int Photodynam 1: 3–5Google Scholar
  102. 101.
    Lipson RL, Baldes EJ (1960) The photodynamic properties of a particular haematoporphyrin derivative. Arch Dermatol 82: 508–516PubMedCrossRefGoogle Scholar
  103. 102.
    Lipson RL, Gray MJ, Baldes EJ (1966) Haematoporphyrin derivative for detection and management of cancer. Proc IX Internat Cancer Congr 393Google Scholar
  104. 103.
    Lui H, Anderson RR (1992) Photodynamic therapy in dermatology. Arch Dermatol 128: 1631–1636PubMedCrossRefGoogle Scholar
  105. 104.
    Lui H, Anderson RR (1993) Photodynamic therapy in dermatology: recent developments. Dermatol Clin n:t -13Google Scholar
  106. 105.
    Lui H, Kollias N, Wimberly J, Anderson RR (1992) Photosensitizing potential of benzoporphyrin derivative-monoacid ring A (BPD-MA) in patients undergoing photo-dynamic therapy. Photochem Photobiol 55 [Suppl]: 30S (abstract)Google Scholar
  107. 106.
    Lui H, Salasche S, Kollias N, Wimberly J, Flotte T, McLean D, Anderson RR (1995) Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch Dermatol 131: 737–738PubMedCrossRefGoogle Scholar
  108. 107.
    Lynch DH, Haddad S, King VJ, Ott MJ, Straight RC, Jolles CJ (1989) Systemic immunosuppression induced by photodynamic therapy ( PDT) is adoptively transferred by macrophages. Photochem Photobiol 49: 453–458Google Scholar
  109. 108.
    Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, Deutsch TF, Anderson RR (1995) Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5–aminolevulinic acid: implications for photo-dynamic treatment. Arch Dermatol Res 287: 665–674PubMedCrossRefGoogle Scholar
  110. 109.
    McCaughan JS Jr, Guy JT, Hicks W, Laufman L, Nims TA, Walker J (1989) Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch Surg 124: 211–216PubMedCrossRefGoogle Scholar
  111. 110.
    McCullough JL, Weinstein GD (1998) Photodynamic therapy of psoriasis. In: Psoriasis (Roenigk HH Jr., Maibach HI, eds.), Marcel Dekker, 3rd ed., New York Basel Hong Kong,pp 757–76oGoogle Scholar
  112. 111.
    Meffert H, Pre§ H, Diezel W, Sönnichsen N (1989) Antipsoriatische und phototoxische Wirksamkeit von Hämatoporphyrin-Derivat nach topischer Applikation und Bestrahlung mit sichtbarem Licht. Dermatol Monatsschr 175: 28–34PubMedGoogle Scholar
  113. 112.
    Meijnders PJN, Star WM, De Bruijn RS, Treurniet-Donker AD, Van Mierlo MJM, Wijthoff SJM, Naafs B, Beerman H, Levendag PC (1996) Clinical results of photodynamic therapy for superficial skin malignancies or actinic keratosis using topical 5–aminolevulinic acid. Las Med Sci 11: 123–131CrossRefGoogle Scholar
  114. 113.
    Milanesi C, Zhou C, Biolo R, Jori G (1990) Zn(II)-phthalocyanine as a photodynamic agent for tumours. II. Studies on the mechanism of photosensitised tumour necrosis. Br J Cancer 61: 846–850Google Scholar
  115. 114.
    Moan J (1986) Porphyrin photosensitization and phototherapy. Photochem Photobiol 43: 681–690PubMedCrossRefGoogle Scholar
  116. 115.
    Monfrecola G, Danna F, Delfino M (1987) Topical hematoporphyrin plus UVA for treatment of alopecia areata. Photodermatol Photoimmunol Photomed 4: 305–306Google Scholar
  117. 116.
    Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM (1996) Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol 135: 766–771PubMedCrossRefGoogle Scholar
  118. 117.
    Nelson JS (1993) Photodynamic therapy of port wine stain: preliminary clinical studies. In: Shapshay SM, Anderson RR, White JV, White RA, Bass LR (eds) Lasers in otolaryngology, dermatology, and tissue welding. Proc SPIE 1876: 142–146Google Scholar
  119. 118.
    North J, Coombs R, Levy JG (1994) Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative. J Acquir Immune Defic Syndr 7: 891–898PubMedGoogle Scholar
  120. 119.
    Nseyo UO, Whalen RK, Duncan MR, Berman B, Lundahl SL (1990) Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report. Urology 36x67–171Google Scholar
  121. 120.
    Nugent LJ, Jain RK (1984) Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238–244PubMedGoogle Scholar
  122. 121.
    Obochi MO, Canaan AJ, Jain AK, Richter AM, Levy JG (1995) Targeting activated lymphocytes with photodynamic therapy: susceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative ( BPD) photosensitization. Photochem Photobiol 62: 169–175Google Scholar
  123. 122.
    Ochsner M (1997) Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B 39a - 18Google Scholar
  124. 123.
    Ortel B, Tanew A, Hönigsmann H (1993) Lethal photosensitization by endogenous porphyrins of PAM cells - modification by desferrioxamine. J Photochem Photobiol B Biol 17: 273–278CrossRefGoogle Scholar
  125. 124.
    Oseroff AR (1993) Photodynamic therapy. In: Lim HW, Soter NA (eds) Clinical photomedicine. Dekker, New York, pp 387–402Google Scholar
  126. 125.
    Pass HI (1993) Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 85:443–456Google Scholar
  127. 126.
    Peng Q, Warloe T, Moan J (1995) Topically-applied ALA-based PDT for nodulo-ulcerative basal cell carcinoma, IPA News 7: 2Google Scholar
  128. 127.
    Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997) 5–Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79: 2282–2308Google Scholar
  129. 128.
    Pennington DG, Waner M, Knox A (1988) Photodynamic therapy for multiple skin cancers. Plast Reconstr Surg 82: 1067–1071PubMedCrossRefGoogle Scholar
  130. 129.
    Pre H, Meffert H, Sönnichsen N (1989) Photodynamische Therapie der Psoriasis palmaris et plantaris mit topisch appliziertem Hämatoporphyrin-Derivat and sichtbarem Licht. Dermatol Monatsschr 175: 745–750Google Scholar
  131. 130.
    Qin B, Selman SH, Payne KM, Keck RW, Metzger DW (1993) Enhanced skin allograft survival after photodynamic therapy. Association with lymphocyte inactivation and macrophage stimulation. Transplantation 56: 1481–1486Google Scholar
  132. 131.
    Raab O (190o) Über die Wirkung fluorescierender Stoffe auf Infusoria. Z Biol 39:524Google Scholar
  133. 132.
    Ratkay LG, Chowdhary RK, Iamaroon A, Richter AM, Neyndorff HC, Keystone EC, Waterfield JD, Levy JG (1998) Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 41: 525–534PubMedCrossRefGoogle Scholar
  134. 133.
    Rebeiz N, Arkins S, Rebeiz CA, Simon J, Zachary JF, Kelley KW (1996) Induction of tumor necrosis by S-aminolevulinic acid and 1,10–phenantroline photodynamic therapy. Cancer Res 56339–344Google Scholar
  135. 134.
    Rebeiz N, Rebeiz CC, Arkins S, Kelley KW, Rebeiz CA (1992) Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: enhancement by 1,10–phenanthroline. Photochem Photobiol 55431–435Google Scholar
  136. 135.
    Reddan J, Anderson CY, Xu H, Hrabovsky S, Freye K, Fairchild R, Tubesing KA, Elmets CA (1999) Immunosuppressive effects of silicon phthalocyanine photodynamic therapy. Photochem Photobiol 70: 72–77PubMedCrossRefGoogle Scholar
  137. 136.
    Renschler MF, Yuen A, Panella TJ, Wieman TJ, Julius C, Panjehpour M, Taber S, Fin-gar V, Horning S, Miller RA, Lowe E, Engel J, Woodburn K, Young SW (1997) Photo-dynamic therapy trials with lutetium texaphyrin PCI-0123 (Lu-Tex). Photochem Photobiol 65: 47S (Abstract)Google Scholar
  138. 137.
    Richert C, Wessels JM, Müller M, Kisters M, Benninghaus T, Goetz AE (1994) Photodynamic antitumor agents: beta-methoxyethyl groups give access to functionalized porphycenes and enhance cellular uptake and activity. J Med Chem 37: 2797–2807PubMedCrossRefGoogle Scholar
  139. 138.
    Richter AM, Jain AK, Canaan AJ, Waterfield E, Sternberg ED, Levy JG (1992) Photosensitizing efficiency of two regioisomers of the benzoporphyrin derivative mono-acid ring A. Biochem Pharmacol 432349–2358Google Scholar
  140. 139.
    Rittenhouse-Diakun K, Van Leengoed H, Morgan J, Hryhorenko E, Paszkiewicz G, Whitaker JE, Oseroff AR (1995) The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid ( ALA ). Photochem Photobiol 61: 523–528Google Scholar
  141. 140.
    Robinson PJ, Carruth JAS, Fairris GM (1988) Photodynamic therapy: a better treatment for widespread Bowen’s disease. Br J Dermatol 119: 59–61PubMedCrossRefGoogle Scholar
  142. 141.
    Rosenblum LA, Hoskwith B, Kramer SD (1937) Photodynamic action of methylene blue on poliomyelitis virus. Proc Soc Exp Biol Med 37: 166–169Google Scholar
  143. 142.
    Rünger TM (1995) Genotoxizität, Mutagenität and Karzinogenität von UVA and UVB. Z Hautkr 70: 877–881Google Scholar
  144. 143.
    Sacchini V, Melloni E, Marchesini R, Fabrizio T, Cascinelli N, Santoro 0, Zunino F, Andreola S, Bandieramonte G (1987) Topical administration of tetrasodium-mesotetraphenyl-porphinesulfonate ( TPPS) and red light irradiation for the treatment of superficial neoplastic lesions. Tumori 73: 19–23Google Scholar
  145. 144.
    Schaffner K, Vogel E, Jori G (1994) Porphycenes as photodynamic therapy agents. In: Jung EG, Holick MF (eds) Biologic effects of light 1993. De Gruyter, Berlin, pp 312–321Google Scholar
  146. 145.
    Schlag P, Hünerbein M, Stern J, Gahlen J, Graschew G (1992) Photodynamische Therapie - Alternative bei lokal rezidiviertem Mamma-Karzinom. Dt Ärztebl 89: 68o - 687Google Scholar
  147. 146.
    Schmidt S, Wagner U, Oehr P, Krebs D (1992) Klinischer Einsatz der photodynamischen Therapie bei gynäkologischen Tumorpatienten - Antikörper-vermittelte photodynamische Lasertherapie als neues onkologisches Behandlungsverfahren. Zentralbl Gynäkol 114: 307–311PubMedGoogle Scholar
  148. 147.
    Schuh M, Nseyo UO, Potter WR, Dao TL, Dougherty TJ (1987) Photodynamic therapy for palliation of locally recurrent breast carcinoma. J Clin Oncol 5: 1766–1770PubMedGoogle Scholar
  149. 148.
    Schultz EW, Krueger AP (1930) Inactivation of staphylococcus bacteriophage by methylene blue. Proc Soc Exp Biol Med 26: 100–101Google Scholar
  150. 149.
    Schwartz SK, Absolon K, Vermund H (1955) Some relationships of porphyrins, x-rays and tumours. Univ Minn Med Bull 27: 7–8Google Scholar
  151. 150.
    Schweitzer VG, Visscher D (1990) Photodynamic therapy for treatment of AIDS-related oral Kaposi’s sarcoma. Otolaryngol Head Neck Surg 102: 639–649PubMedGoogle Scholar
  152. 151.
    Silver H (1937) Psoriasis vulgaris treated with hematoporphyrin. Arch Dermatol Syph 36: 1118–1119Google Scholar
  153. 152.
    Sperduto PW, DeLaney TF, Thomas G, Smith P, Dachowski LJ, Russo A, Bonner R, Glatstein E (1991) Photodynamic therapy for chest wall recurrence in breast cancer. Int J Radiat Oncol Biol Phys 21: 441–446PubMedCrossRefGoogle Scholar
  154. 153.
    Star WM, Marijnissen HP, van den Berg Blok AE, Versteeg JA, Franken KA, Reinhold HS (1986) Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 46: 2532–254oGoogle Scholar
  155. 154.
    Stender IM, Na R, Fogh H, Glaud C, Wulf HC (woo) Photodynamic therapy with 5aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomized double-blind trial. Lancet 355: 963–966Google Scholar
  156. 155.
    Stern R, Zierler S, Parrish JA (1982) Psoriasis and the risk of cancer. J Invest Dermatol 78: 147–149PubMedCrossRefGoogle Scholar
  157. 156.
    Svaasand LO, Tromberg BJ, Wyss P, Wyss-Desserich MT, Tadir Y, Berns MW (1996) Light and drug distribution with topically administered photosensitizers. Las Med Sci 11: 261–265CrossRefGoogle Scholar
  158. 157.
    Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, Berg R, Johansson J, Svanberg S (1994) Photodynamic therapy of non-melanoma malignant tumours of the skin using topical 6–amino levulinic acid sensitization and laser irradiation. Br J Dermatol 13o: 743–751CrossRefGoogle Scholar
  159. 158.
    Szeimies RM, Abels C, Fritsch C, Karrer S, Steinbach P, Bäumler W, Goerz G, Goetz AE, Landthaler M (1995) Wavelength dependency of photodynamic effects after sensitization with 5–aminolevulinic acid in vitro and in vivo. J Invest Dermatol 105: 672–677PubMedCrossRefGoogle Scholar
  160. 159.
    Szeimies RM, Hein R, Bäumler W, Heine A, Landthaler M (1994) A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol (Stockh) 74x17–119Google Scholar
  161. 160.
    Szeimies RM, Karrer S, Heine A, Hohenleutner U, Landthaler M (1995) Topical photodynamic therapy with 5–aminolevulinic acid in the treatment of arsenic-induced skin tumors. Eur J Dermatol 5: 208–211CrossRefGoogle Scholar
  162. 161.
    Szeimies RM, Karrer S, Sauerwald A, Landthaler M (1996b) Topical photodynamic therapy with 5–aminolevulinic acid in the treatment of actinic keratoses: a first clinical study. Dermatology 192: 246–251PubMedCrossRefGoogle Scholar
  163. 162.
    Szeimies RM, Landthaler M (1993) Treatment of Bowen’s disease with topical photo-dynamic therapy. J Dermatol Treat 4: 207–209CrossRefGoogle Scholar
  164. 163.
    Szeimies RM, Landthaler M (1995) Topische photodynamische Therapie in der Behandlung oberflächlicher Hauttumoren. Hautarzt 46: 315–318PubMedCrossRefGoogle Scholar
  165. 164.
    Szeimies RM, Sassy T, Landthaler M (1994) Penetration potency of topical applied 6aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol 59: 73–76PubMedCrossRefGoogle Scholar
  166. 165.
    Taber SW, Fingar VH, Coots CT, Wieman TJ (1998) Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clin Cancer Res 4: 2741–2746PubMedGoogle Scholar
  167. 166.
    Thiele B, Grotmann P, Hüttmann G, Diddens H, Hörauf H (1994) Topische photodynamische Therapie (TPDT) von Basaliomen: klinische, histologische und experimentelle Ergebnisse (erste Mitteilung). Z Hautkr 3: 161–164Google Scholar
  168. 167.
    Tse DT, Kersten RD, Anderson RL (1984) Hematoporphyrin derivative photoradiation therapy in managing nevoid basal cell carcinoma syndrome. Arch Ophthalmol 102: 990–994PubMedCrossRefGoogle Scholar
  169. 168.
    Vogel E, Köcher M, Schmickler H, Lex J (1986) Porphycene - a novel porphin isomer. Angew Chem 98: 262–264CrossRefGoogle Scholar
  170. 169.
    von Tappeiner H, Jesionek A (1903) Therapeutische Versuche mit fluorescierenden Stoffen. Munch Med Wochenschr 47: 2042–2044Google Scholar
  171. 170.
    Wainwright M (1998) Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 42: 13–28PubMedCrossRefGoogle Scholar
  172. 171.
    Waldow SM, Lobraico RV, Kohler IK, Wallk S, Fritts HT (1987) Photodynamic therapy for treatment of malignant cutaneous lesions. Lasers Surg Med 7: 451–456PubMedCrossRefGoogle Scholar
  173. 172.
    Walter AW, Pivnick EK, Bale AE, Kun LE (1997) Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol 19: 258–262PubMedCrossRefGoogle Scholar
  174. 173.
    Warloe T, Peng Q, Moan J, Qvist HL, Giercksky KE (1992) Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5–aminolevulinic acid. In: Spinelli P, Dal Fante M, Marchesini R (eds) Photodynamic therapy and biomedical lasers. Elsevier Science, Amsterdam, pp 449–453Google Scholar
  175. 174.
    Weinstein GD, McCullough JL, Jeffes EW, Nelson JS, Fong NL, McCormick AJ (1994) Photodynamic therapy (PDT) of psoriasis with topical delta aminolevulinic acid (ALA): a pilot dose ranging study. Photodermatol Photoimmunol Photomed 10: 92 (abstract)Google Scholar
  176. 175.
    Weinstein GD, McCullough JL, Nelson JS, Berns MW, McCormick AJ (1991) Low-dose photofrin II photodynamic therapy of psoriasis. Clin Res 39: 509A (abstract)Google Scholar
  177. 176.
    Weishaupt KR, Gomer CJ, Dougherty TJ (1976) Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res 36: 2326–2329PubMedGoogle Scholar
  178. 177.
    Wennberg AM, Lindholm LE, Alpsten M, Larkö 0 (1996) Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 288: 561–564Google Scholar
  179. 178.
    Wessels JM, Strauss W, Seidlitz HK, Rück A, Schneckenburger H (1992) Intracellular localization of meso-tetraphenylporphine tetrasulphonate probed by time-resolved and microscopic fluorescence spectroscopy. J Photochem Photobiol B Biol 12: 275–284CrossRefGoogle Scholar
  180. 179.
    Wilson BD, Mang TS, Cooper M, Stoll H (1989) Use of photodynamic therapy for the treatment of extensive basal cell carcinomas. Facial Plast Surg 6: 185–189PubMedCrossRefGoogle Scholar
  181. 180.
    Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ (1992) Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 128x597–1601Google Scholar
  182. 181.
    Winkelman JW, Collins GH (1987) Neurotoxicity of tetraphenylporphinesulfonate TPPS4 and its relation to photodynamic therapy. Photochem-Photobiol 46: 801–807PubMedCrossRefGoogle Scholar
  183. 182.
    Wolf P, Fink-Puches R, Cerroni L, Kerl H (1994) Photodynamic therapy for mycosis fungoides after topical photosensitization with 5–aminolevulinic acid. J Am Acad Dermatol 31: 678–68oPubMedCrossRefGoogle Scholar
  184. 183.
    Wolf P, Fink-Puches R, Kerl H (1995) Photodynamic therapy for mycosis fungoides after topical photosensitization with 5–aminolevulinic acid. J Am Acad Dermatol 33: 541CrossRefGoogle Scholar
  185. 184.
    Wolf P, Kerl H (1995) Photodynamic therapy with 5–aminolevulinic acid: a promising concept for the treatment of cutaneous tumors. Dermatology 190: 183–185PubMedCrossRefGoogle Scholar
  186. 185.
    Wolf P, Rieger E, Kerl H (1993) Topical photo dynamic therapy with endogenous porphyrins after application of 5–aminolevulinic acid. J Am Acad Dermatol 28: 17–21PubMedCrossRefGoogle Scholar
  187. 186.
    Wolford ST, Novicki DL, Kelly B (1995) Comparative skin phototoxicity in mice with two photosensitizing drugs: Benzoporphyrin derivative monoacid ring A and porfimer sodium ( Photofrin ). Fundam Appl Toxicol 24: 52–56Google Scholar
  188. 187.
    Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Phillips DR (1991) Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem Photobiol 54: 725–732PubMedCrossRefGoogle Scholar
  189. 188.
    Xiao-xi L, Wie W, Shuo-fan W, Chuan Y, Ti-Sheng C (1997) Treatment of capillary vascular malformation (port-wine stains) with photochemotherapy. Plast Reconstr Surg 99: 1826–1830CrossRefGoogle Scholar
  190. 189.
    Yamamoto N, Hoober JK, Yamamoto N, Yamamoto S (1992) Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem Photobiol 56: 245–250PubMedCrossRefGoogle Scholar
  191. 190.
    Yamamoto N; Sery TW; Hoober JK; Willett NP; Lindsay DD (1994) Effectiveness of photofrin II in activation of macrophages and in vitro killing of retinoblastoma cells. Photochem Photobiol 6oa6o -164Google Scholar
  192. 191.
    Zaidi SI; Oleinick NL; Zaim MT; Mukhtar H (1993) Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 58: 771–776PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Rolf-Markus Szeimies
  • Sigrid Karrer
  • Christoph Abels
  • Michael Landthaler
  • Craig A. Elmets

There are no affiliations available

Personalised recommendations